ALNYLAM PHARMACEUTICALS INC

20 February, 2025

Alnylam Pharmaceuticals Maintains 2024 Loss Estimate, Predicts Solid Profit Growth for 2025 Amid Positive Market Sentiment

Alnylam Pharmaceuticals is demonstrating strong momentum as it approaches 2025, maintaining its loss per share estimate for 2024 at 39 cents while projecting a turnaround with expected earnings of 41 ...
Read More

19 February, 2025

Alnylam Pharmaceuticals' Earnings Projections Show Significant Improvement, Stock Rises 74.4% Over Past Year

Alnylam Pharmaceuticals has recently experienced notable improvements in its earnings projections, marking a significant turnaround from forecasts of a loss to anticipated profitability. For the fisca...
Read More

15 February, 2025

Alnylam Pharmaceuticals Maintains Strong Zacks Ranking with Positive Earnings Outlook Despite Projected Losses for 2024

Alnylam Pharmaceuticals (ALNY) continues to showcase resilience in the biotech space, currently holding a Zacks Rank of #2 (Buy). As of mid-February 2025, the company's earnings estimates indicate a l...
Read More

14 February, 2025

Alnylam Pharmaceuticals Maintains Strong Zacks Ranking with Positive Earnings Outlook Despite Projected Losses for 2024

Alnylam Pharmaceuticals (ALNY) continues to showcase resilience in the biotech space, currently holding a Zacks Rank of #2 (Buy). As of mid-February 2025, the company's earnings estimates indicate a l...
Read More